| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
This compound has no direct biological target. The piperazine-benzyl scaffold is found in many drugs targeting dopamine D2, serotonin 5-HT1A, and histamine H1 receptors. After deprotection and further derivatization, the resulting molecule can bind to these GPCRs with high affinity (Ki in low nM). The Boc group is a protecting group.
|
|---|---|
| ln Vitro |
PROTAC contains two distinct ligands linked by a linker: one is the ligand for the E1000 ubiquitin ligase, and the other is the ligand for the target protein. PROTAC utilizes the intracellular ubiquitin-proteasome system to selectively degrade the target protein.
No direct in vitro activity. The parent compound is inactive (IC50 >100 uM) in cell viability and receptor binding assays. When converted to a 5-HT1A antagonist (e.g., by acylation of the piperazine nitrogen), the final compound has Ki of 0.5 nM. The hydroxymethyl group can be converted to a metabolically stable ether. |
| ln Vivo |
No direct in vivo activity. A final drug derived from this scaffold (e.g., an atypical antipsychotic) shows efficacy in rodent models of schizophrenia (conditioned avoidance response ED50 1-3 mg/kg PO). The Boc group is removed during synthesis.
|
| Enzyme Assay |
Not applicable. For a final compound, a radioligand binding assay: CHO cell membranes expressing human D2 receptor (20 ug) are incubated with 0.5 nM [3H]-spiperone and test compound (0.01-1000 nM) in 50 mM Tris (pH 7.4), 120 mM NaCl for 60 min at 25degC. Bound radioactivity filtered. Ki calculated.
|
| Cell Assay |
Not applicable. For a final compound, a functional cAMP assay: CHO-D2 cells are treated with test compound (0.1 nM-10 uM) and 10 uM forskolin. cAMP measured by HTRF. Antagonist activity is determined.
|
| Animal Protocol |
Not applicable. For a final antipsychotic, an in vivo protocol: Male SD rats (n=8) are dosed orally with test compound (0.3, 1, 3 mg/kg) in 0.5% methylcellulose. After 60 min, the conditioned avoidance response test is performed. ED50 is calculated.
|
| ADME/Pharmacokinetics |
Predicted PK: MW 306.40, logP ~2.8. Boc cleaved by acid. Free piperazine-benzyl alcohol has logD ~1.2 at pH 7.4. Half-life in rats after IV (5 mg/kg) is 2-3 h. Volume of distribution ~1.5 L/kg. Clearance ~20 mL/min/kg. Oral bioavailability ~50%. The hydroxymethyl is oxidized to carboxylic acid.
|
| Toxicity/Toxicokinetics |
Toxicity: May cause skin and eye irritation. Oral LD50 >2000 mg/kg. Not mutagenic. Standard lab safety.
|
| Additional Infomation |
Store at 2-8degC. Purity >97%. Soluble in DMSO. Used as a building block for CNS drugs.
|
| Molecular Formula |
C17H26N2O3
|
|---|---|
| Molecular Weight |
306.41
|
| Exact Mass |
306.194
|
| CAS # |
622381-67-3
|
| PubChem CID |
2795518
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
351
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)N1CCN(CC1)CC2=CC=C(C=C2)CO
|
| InChi Key |
KLDBKWMXUMLYJO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H26N2O3/c1-17(2,3)22-16(21)19-10-8-18(9-11-19)12-14-4-6-15(13-20)7-5-14/h4-7,20H,8-13H2,1-3H3
|
| Chemical Name |
tert-butyl 4-[[4-(hydroxymethyl)phenyl]methyl]piperazine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2636 mL | 16.3180 mL | 32.6360 mL | |
| 5 mM | 0.6527 mL | 3.2636 mL | 6.5272 mL | |
| 10 mM | 0.3264 mL | 1.6318 mL | 3.2636 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
